AU2012257490A1 - Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism - Google Patents
Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism Download PDFInfo
- Publication number
- AU2012257490A1 AU2012257490A1 AU2012257490A AU2012257490A AU2012257490A1 AU 2012257490 A1 AU2012257490 A1 AU 2012257490A1 AU 2012257490 A AU2012257490 A AU 2012257490A AU 2012257490 A AU2012257490 A AU 2012257490A AU 2012257490 A1 AU2012257490 A1 AU 2012257490A1
- Authority
- AU
- Australia
- Prior art keywords
- testosterone
- gel formulation
- gel
- mixture
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims abstract description 825
- 229960003604 testosterone Drugs 0.000 title claims abstract description 413
- 239000000203 mixture Substances 0.000 title claims abstract description 385
- 238000009472 formulation Methods 0.000 title claims abstract description 235
- 239000000227 bioadhesive Substances 0.000 title abstract description 12
- 201000003585 eunuchism Diseases 0.000 title description 16
- 208000037106 male hypogonadism Diseases 0.000 title description 16
- 238000000034 method Methods 0.000 claims abstract description 87
- 206010058359 Hypogonadism Diseases 0.000 claims abstract description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 177
- 239000004359 castor oil Substances 0.000 claims description 111
- 235000019438 castor oil Nutrition 0.000 claims description 111
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 111
- 239000002904 solvent Substances 0.000 claims description 29
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 26
- 206010002261 Androgen deficiency Diseases 0.000 claims description 22
- 238000009165 androgen replacement therapy Methods 0.000 claims description 22
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 20
- 238000009792 diffusion process Methods 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000000080 wetting agent Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 315
- 230000002950 deficient Effects 0.000 abstract description 5
- 230000002459 sustained effect Effects 0.000 abstract description 5
- 239000000499 gel Substances 0.000 description 281
- 229960001777 castor oil Drugs 0.000 description 109
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 106
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 89
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 85
- 229910052681 coesite Inorganic materials 0.000 description 73
- 229910052906 cristobalite Inorganic materials 0.000 description 73
- 229910052682 stishovite Inorganic materials 0.000 description 73
- 238000012360 testing method Methods 0.000 description 73
- 229910052905 tridymite Inorganic materials 0.000 description 73
- 238000007792 addition Methods 0.000 description 72
- 210000002966 serum Anatomy 0.000 description 68
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 63
- 239000000377 silicon dioxide Substances 0.000 description 56
- 235000012239 silicon dioxide Nutrition 0.000 description 55
- 239000003814 drug Substances 0.000 description 54
- 229940079593 drug Drugs 0.000 description 50
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 46
- 229960005309 estradiol Drugs 0.000 description 42
- 229930182833 estradiol Natural products 0.000 description 42
- 239000000825 pharmaceutical preparation Substances 0.000 description 38
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 37
- 229960003473 androstanolone Drugs 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 37
- 229940126534 drug product Drugs 0.000 description 34
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 230000008569 process Effects 0.000 description 31
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 30
- 239000012535 impurity Substances 0.000 description 30
- 239000012530 fluid Substances 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 25
- 238000005070 sampling Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 230000002411 adverse Effects 0.000 description 23
- 230000008859 change Effects 0.000 description 22
- 230000007423 decrease Effects 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 239000003921 oil Substances 0.000 description 20
- 235000019198 oils Nutrition 0.000 description 20
- 239000006185 dispersion Substances 0.000 description 19
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 18
- 238000001647 drug administration Methods 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 229920003082 Povidone K 90 Polymers 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 230000000813 microbial effect Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 239000002994 raw material Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229920003081 Povidone K 30 Polymers 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 12
- 238000005259 measurement Methods 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- -1 polyethylene Chemical class 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 238000012546 transfer Methods 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 11
- 229940126602 investigational medicinal product Drugs 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 230000000699 topical effect Effects 0.000 description 11
- 206010067484 Adverse reaction Diseases 0.000 description 10
- 206010059594 Secondary hypogonadism Diseases 0.000 description 10
- 238000004364 calculation method Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000006838 adverse reaction Effects 0.000 description 9
- 238000004820 blood count Methods 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 101100313150 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TBS1 gene Proteins 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000003098 androgen Substances 0.000 description 8
- 239000006184 cosolvent Substances 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 125000005456 glyceride group Chemical class 0.000 description 8
- 210000002850 nasal mucosa Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 210000002307 prostate Anatomy 0.000 description 8
- 239000013074 reference sample Substances 0.000 description 8
- 102000009151 Luteinizing Hormone Human genes 0.000 description 7
- 108010073521 Luteinizing Hormone Proteins 0.000 description 7
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940088679 drug related substance Drugs 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000005414 inactive ingredient Substances 0.000 description 7
- 229940040129 luteinizing hormone Drugs 0.000 description 7
- 210000003928 nasal cavity Anatomy 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229910052710 silicon Inorganic materials 0.000 description 7
- 239000010703 silicon Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000001364 causal effect Effects 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000013102 re-test Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000009974 thixotropic effect Effects 0.000 description 6
- 238000002562 urinalysis Methods 0.000 description 6
- 206010010356 Congenital anomaly Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 239000004698 Polyethylene Chemical class 0.000 description 5
- 239000004743 Polypropylene Substances 0.000 description 5
- 206010052649 Primary hypogonadism Diseases 0.000 description 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 5
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229940030486 androgens Drugs 0.000 description 5
- 208000007502 anemia Diseases 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 235000020937 fasting conditions Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 210000001331 nose Anatomy 0.000 description 5
- 229920000573 polyethylene Chemical class 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 102220037545 rs187184327 Human genes 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000002211 ultraviolet spectrum Methods 0.000 description 5
- 229940116269 uric acid Drugs 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 241000189705 Dunedin group Species 0.000 description 4
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 239000005030 aluminium foil Substances 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- 150000001557 benzodiazepines Chemical class 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 229920001903 high density polyethylene Polymers 0.000 description 4
- 239000004700 high-density polyethylene Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000036387 respiratory rate Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 229920003072 Plasdone™ povidone Polymers 0.000 description 3
- 208000008601 Polycythemia Diseases 0.000 description 3
- 229920000297 Rayon Polymers 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000002199 base oil Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000001839 endoscopy Methods 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000009975 flexible effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 241001550224 Apha Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000009025 Endorphins Human genes 0.000 description 2
- 108010049140 Endorphins Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 101000711466 Homo sapiens SAM pointed domain-containing Ets transcription factor Proteins 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033296 Overdoses Diseases 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 2
- 102100034018 SAM pointed domain-containing Ets transcription factor Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 229940070021 anabolic steroids Drugs 0.000 description 2
- 238000012863 analytical testing Methods 0.000 description 2
- 238000013103 analytical ultracentrifugation Methods 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 2
- 229960005471 androstenedione Drugs 0.000 description 2
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 229960003608 clomifene Drugs 0.000 description 2
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 238000010960 commercial process Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 201000000160 cryptorchidism Diseases 0.000 description 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940061795 dristan 12-hour nasal spray Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229960004199 dutasteride Drugs 0.000 description 2
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960003399 estrone Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 229920003112 high viscosity grade hydroxypropyl cellulose Polymers 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000002332 leydig cell Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229920003117 medium viscosity grade hydroxypropyl cellulose Polymers 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 210000000492 nasalseptum Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100001079 no serious adverse effect Toxicity 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 229960001528 oxymetazoline Drugs 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229960000249 pregnenolone Drugs 0.000 description 2
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000003237 recreational drug Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 102220200885 rs141929755 Human genes 0.000 description 2
- 102220127608 rs886044631 Human genes 0.000 description 2
- 238000009517 secondary packaging Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960000835 tadalafil Drugs 0.000 description 2
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 2
- 229960005353 testolactone Drugs 0.000 description 2
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 229960002381 vardenafil Drugs 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002652 Anorgasmia Diseases 0.000 description 1
- 206010002961 Aplasia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010005133 Bleeding tendencies Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- 206010011498 Cryptorchism Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 102000007513 Hemoglobin A Human genes 0.000 description 1
- 108010085682 Hemoglobin A Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- 201000007493 Kallmann syndrome Diseases 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 208000008111 Leydig cell hypoplasia Diseases 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 208000026344 Nasal disease Diseases 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010053142 Olfacto genital dysplasia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010064022 Prostatic mass Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100005430 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) cpsA1 gene Proteins 0.000 description 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000028347 Sinus disease Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229940059312 androderm Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- XEGGRYVFLWGFHI-UHFFFAOYSA-N bendiocarb Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)O2 XEGGRYVFLWGFHI-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical class OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 208000022119 inability to concentrate Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 231100000794 masculinization Toxicity 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 229940100652 nasal gel Drugs 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000002435 rhinoplasty Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000035936 sexual power Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229940103651 testosterone enanthate 200 mg/ml Drugs 0.000 description 1
- 229940078749 testosterone nasal gel Drugs 0.000 description 1
- 229960000746 testosterone undecanoate Drugs 0.000 description 1
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 239000003017 thermal stabilizer Substances 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012976 trial formulation Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017203470A AU2017203470A1 (en) | 2011-05-15 | 2017-05-24 | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
| AU2019201618A AU2019201618A1 (en) | 2011-05-15 | 2019-03-08 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
| AU2020210227A AU2020210227A1 (en) | 2011-05-15 | 2020-07-29 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
| AU2022202402A AU2022202402A1 (en) | 2011-05-15 | 2022-04-12 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
| AU2024216312A AU2024216312A1 (en) | 2011-05-15 | 2024-08-23 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486324P | 2011-05-15 | 2011-05-15 | |
| US61/486,324 | 2011-05-15 | ||
| US201161486634P | 2011-05-16 | 2011-05-16 | |
| US61/486,634 | 2011-05-16 | ||
| PCT/IB2012/001112 WO2012156820A1 (en) | 2011-05-15 | 2012-05-15 | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017203470A Division AU2017203470A1 (en) | 2011-05-15 | 2017-05-24 | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2012257490A1 true AU2012257490A1 (en) | 2013-12-19 |
Family
ID=46579248
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012257490A Abandoned AU2012257490A1 (en) | 2011-05-15 | 2012-05-15 | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
| AU2012257492A Abandoned AU2012257492A1 (en) | 2011-05-15 | 2012-05-15 | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| AU2017203470A Abandoned AU2017203470A1 (en) | 2011-05-15 | 2017-05-24 | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
| AU2017204182A Abandoned AU2017204182A1 (en) | 2011-05-15 | 2017-06-20 | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| AU2019201618A Abandoned AU2019201618A1 (en) | 2011-05-15 | 2019-03-08 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
| AU2019203067A Abandoned AU2019203067A1 (en) | 2011-05-15 | 2019-04-30 | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| AU2019203400A Abandoned AU2019203400A1 (en) | 2011-05-15 | 2019-05-15 | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| AU2020210227A Abandoned AU2020210227A1 (en) | 2011-05-15 | 2020-07-29 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
| AU2020267162A Ceased AU2020267162B2 (en) | 2011-05-15 | 2020-11-09 | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| AU2022202402A Abandoned AU2022202402A1 (en) | 2011-05-15 | 2022-04-12 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
| AU2024216312A Pending AU2024216312A1 (en) | 2011-05-15 | 2024-08-23 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
Family Applications After (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012257492A Abandoned AU2012257492A1 (en) | 2011-05-15 | 2012-05-15 | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| AU2017203470A Abandoned AU2017203470A1 (en) | 2011-05-15 | 2017-05-24 | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
| AU2017204182A Abandoned AU2017204182A1 (en) | 2011-05-15 | 2017-06-20 | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| AU2019201618A Abandoned AU2019201618A1 (en) | 2011-05-15 | 2019-03-08 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
| AU2019203067A Abandoned AU2019203067A1 (en) | 2011-05-15 | 2019-04-30 | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| AU2019203400A Abandoned AU2019203400A1 (en) | 2011-05-15 | 2019-05-15 | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| AU2020210227A Abandoned AU2020210227A1 (en) | 2011-05-15 | 2020-07-29 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
| AU2020267162A Ceased AU2020267162B2 (en) | 2011-05-15 | 2020-11-09 | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| AU2022202402A Abandoned AU2022202402A1 (en) | 2011-05-15 | 2022-04-12 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
| AU2024216312A Pending AU2024216312A1 (en) | 2011-05-15 | 2024-08-23 | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism |
Country Status (16)
| Country | Link |
|---|---|
| EP (3) | EP3977982A1 (enExample) |
| JP (9) | JP2014513716A (enExample) |
| KR (10) | KR102088038B1 (enExample) |
| CN (4) | CN109481394B (enExample) |
| AR (2) | AR089553A1 (enExample) |
| AU (11) | AU2012257490A1 (enExample) |
| BR (2) | BR112013029336B1 (enExample) |
| CA (3) | CA2836405C (enExample) |
| DK (1) | DK2714006T3 (enExample) |
| EA (1) | EA201391701A1 (enExample) |
| ES (1) | ES2859784T3 (enExample) |
| IL (2) | IL229401A0 (enExample) |
| MX (4) | MX2013013369A (enExample) |
| PL (1) | PL2714006T3 (enExample) |
| WO (2) | WO2012156822A1 (enExample) |
| ZA (2) | ZA201309264B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| KR102088038B1 (ko) * | 2011-05-15 | 2020-03-13 | 에이세러스 바이오파마 인크. | 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템 |
| US8971800B2 (en) * | 2011-05-31 | 2015-03-03 | Qualcomm Incorporated | Methods and apparatus for improving NFC activation and data exchange reporting mechanisms |
| ES2885523T3 (es) | 2011-11-23 | 2021-12-14 | Therapeuticsmd Inc | Formulaciones y terapias de reposición hormonal de combinación naturales |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150297733A1 (en) * | 2012-11-14 | 2015-10-22 | Trimel Biopharma Srl | Controlled release topical testosterone formulations and methods |
| US20140171918A1 (en) * | 2012-12-14 | 2014-06-19 | Bioject, Inc. | Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| ES2749588T3 (es) * | 2013-10-07 | 2020-03-23 | Antares Pharma Inc | Modulación de hematocrito mediante inyección de testosterona a chorro asistida por aguja |
| WO2015127012A1 (en) | 2014-02-19 | 2015-08-27 | Wotton Paul K | Needle assisted jet injection administration of testosterone compositions |
| WO2015179782A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| KR20170040209A (ko) | 2014-07-29 | 2017-04-12 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 경피 크림 |
| TW201636045A (zh) * | 2015-01-28 | 2016-10-16 | 波美西恩製藥有限責任公司 | 組成物、促進或增強受試者之局部毛髮飽滿度及厚度或毛髮生長之方法、包括該組成物之套組及裝置 |
| CA2986444C (en) * | 2015-06-29 | 2023-10-24 | 480 Biomedical, Inc. | Implantable scaffolds for treatment of sinusitis |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| BR102015020878B1 (pt) * | 2015-08-28 | 2019-08-27 | F B M Ind Farmaceutica Ltda | formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona. |
| EP3399963B1 (en) * | 2016-01-07 | 2023-06-07 | Viramal Limited | Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017187262A1 (en) | 2016-04-25 | 2017-11-02 | Marc Andrew Koska | Medical delivery system |
| MX392668B (es) * | 2016-06-02 | 2025-03-24 | Acerus Labs Inc | Composiciones nasales de cannabidiol |
| WO2017208209A1 (en) * | 2016-06-03 | 2017-12-07 | M et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
| HUE063346T2 (hu) * | 2017-01-20 | 2024-01-28 | M et P Pharma AG | Nazális gyógyszerészeti készítmények légszennyezõ anyagoknak való kitettség kockázatainak csökkentésére |
| JP6961729B2 (ja) * | 2017-06-17 | 2021-11-05 | エルジー エレクトロニクス インコーポレイティドLg Electronics Inc. | 無線通信システムにおける端末の登録方法およびそのための装置 |
| EP3710086A4 (en) | 2017-11-17 | 2021-11-17 | Koska Family Limited | SYSTEMS AND PROCESSES FOR FLUID DISPENSERS |
| CN111386119A (zh) * | 2017-11-27 | 2020-07-07 | Aska制药株式会社 | 粉末鼻腔给药制剂 |
| KR20200118039A (ko) | 2018-02-02 | 2020-10-14 | 아세러스 바이오파마 인크. | 테스토스테론 요법의 방법 |
| WO2019175290A1 (en) | 2018-03-13 | 2019-09-19 | Beckley Canopy Therapeutics Limited | Cannabis or cannabis derived compositions for promoting cessation of chemical dependence |
| CN108771622B (zh) * | 2018-07-11 | 2022-01-07 | 尹振图 | 一种自闭式针形滴嘴及眼药水瓶 |
| CN113164384A (zh) | 2018-10-26 | 2021-07-23 | 维拉莫有限公司 | 黏膜粘附性凝胶组合物 |
| ES2948955T3 (es) | 2018-11-30 | 2023-09-22 | Viramal Ltd | Un método de preparación de un agente gelificante, el agente gelificante obtenido de este modo y el uso de dicho agente gelificante |
| US20200170962A1 (en) | 2018-11-30 | 2020-06-04 | F. Markus Leweke | Nasal cannabidiol compositions |
| WO2020118437A1 (en) * | 2018-12-14 | 2020-06-18 | Acerus Biopharma Inc. | Active ester derivatives of testosterone, compositions and uses thereof |
| USD1052082S1 (en) | 2020-06-01 | 2024-11-19 | Koska Family Limited | Sealed fluid container |
| CN112121049B (zh) * | 2020-08-28 | 2022-02-01 | 嘉兴市第一医院 | 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用 |
| EP4247332A1 (en) * | 2020-11-19 | 2023-09-27 | Acousia Therapeutics GmbH | Non-aqueous gel composition |
| GB202307501D0 (en) * | 2023-05-19 | 2023-07-05 | Lawley Pharmaceuticals Pty Ltd | Process for preparing dispensable testosterone cream |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082881A (en) * | 1976-12-23 | 1978-04-04 | E. R. Squibb & Sons, Inc. | Topical and other type pharmaceutical formulations containing isosorbide carrier |
| DE4214953C2 (de) | 1992-05-06 | 1995-05-18 | Arrowdean Ltd | Arzneimittel zur Erhöhung des Testosteronspiegels |
| US5756071A (en) | 1992-06-03 | 1998-05-26 | Arrowdean Limited | Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier |
| DE4405898A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| US5576071A (en) | 1994-11-08 | 1996-11-19 | Micron Technology, Inc. | Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds |
| JP2000514065A (ja) * | 1997-07-03 | 2000-10-24 | アルザ コーポレイション | ドラッグデリバリーディバイスとその製造法 |
| ATE418988T1 (de) * | 1997-11-10 | 2009-01-15 | Strakan Int Ltd | Penetrationsfördernde und irritationsvermindernde systeme mit testosteron |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| DE10064950A1 (de) * | 2000-12-23 | 2002-07-11 | Impetus Ag Basel | Thixotropes Nasenspray |
| EP1450739A4 (en) * | 2001-10-12 | 2008-12-17 | Cns Inc | NASAL MOISTURIZING GEL AND APPLICATOR |
| MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
| IL152575A (en) * | 2002-10-31 | 2008-12-29 | Transpharma Medical Ltd | A skin-to-skin transmission system of water-insoluble drugs |
| JP5619337B2 (ja) * | 2003-10-10 | 2014-11-05 | フェリング ビー．ブイ． | 皮膚残渣を最小限に抑えるための経皮的医薬製剤 |
| ATE319426T1 (de) * | 2003-11-11 | 2006-03-15 | Mattern Udo | Nasenformulierung mit kontrollierter freisetzung von sexualhormonen |
| BRPI0518853A2 (pt) * | 2004-12-09 | 2008-12-09 | Bayer Healthcare Ag | estabilizaÇço de Ésteres de glicocorticàides com Ácidos |
| MX2007015255A (es) * | 2005-06-03 | 2008-02-22 | Acrux Dds Pty Ltd | Metodo y composicion para administracion transdermica de un farmaco. |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| CN101099742A (zh) * | 2006-07-06 | 2008-01-09 | 上海富海科申药业有限公司 | 能够减少皮肤刺激的睾酮凝胶制剂 |
| AU2007304471B2 (en) * | 2006-10-04 | 2012-09-06 | M & P Patent Aktiengesellschaft | Controlled release delivery system for nasal application of neurotransmitters |
| EA018775B1 (ru) * | 2007-03-23 | 2013-10-30 | Юнимед Фармасьютикалз Ллк | Применение тестостерона в форме водно-спиртового геля для лечения детского гипогонадизма |
| CN101801388B (zh) * | 2007-09-20 | 2012-07-04 | 株式会社资生堂 | 透皮吸收制剂 |
| DK2949361T3 (en) * | 2007-11-13 | 2017-07-03 | Athenion Ag | C-19 STEROIDS FOR CELLULITE TREATMENT |
| GB0807605D0 (en) * | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
| KR102088038B1 (ko) * | 2011-05-15 | 2020-03-13 | 에이세러스 바이오파마 인크. | 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템 |
-
2012
- 2012-05-15 KR KR1020187038088A patent/KR102088038B1/ko active Active
- 2012-05-15 EP EP21191386.8A patent/EP3977982A1/en not_active Withdrawn
- 2012-05-15 MX MX2013013369A patent/MX2013013369A/es unknown
- 2012-05-15 WO PCT/IB2012/001127 patent/WO2012156822A1/en not_active Ceased
- 2012-05-15 BR BR112013029336-5A patent/BR112013029336B1/pt active IP Right Grant
- 2012-05-15 AU AU2012257490A patent/AU2012257490A1/en not_active Abandoned
- 2012-05-15 MX MX2019003340A patent/MX374398B/es active IP Right Grant
- 2012-05-15 EP EP12748245.3A patent/EP2714006B1/en active Active
- 2012-05-15 KR KR1020217036024A patent/KR20210135003A/ko not_active Ceased
- 2012-05-15 MX MX2020008599A patent/MX395212B/es unknown
- 2012-05-15 KR KR1020207006630A patent/KR20200028503A/ko not_active Ceased
- 2012-05-15 KR KR1020247037387A patent/KR20240162608A/ko active Pending
- 2012-05-15 WO PCT/IB2012/001112 patent/WO2012156820A1/en not_active Ceased
- 2012-05-15 ES ES12748245T patent/ES2859784T3/es active Active
- 2012-05-15 CN CN201811198846.5A patent/CN109481394B/zh active Active
- 2012-05-15 PL PL12748245T patent/PL2714006T3/pl unknown
- 2012-05-15 MX MX2013013388A patent/MX363561B/es unknown
- 2012-05-15 AU AU2012257492A patent/AU2012257492A1/en not_active Abandoned
- 2012-05-15 DK DK12748245.3T patent/DK2714006T3/da active
- 2012-05-15 JP JP2014510900A patent/JP2014513716A/ja active Pending
- 2012-05-15 CA CA2836405A patent/CA2836405C/en active Active
- 2012-05-15 KR KR1020217007047A patent/KR102568894B1/ko active Active
- 2012-05-15 KR KR1020137033181A patent/KR20140045400A/ko not_active Ceased
- 2012-05-15 CA CA2836398A patent/CA2836398C/en active Active
- 2012-05-15 CN CN201280035162.8A patent/CN103813784A/zh active Pending
- 2012-05-15 CN CN201910982324.2A patent/CN110613679A/zh active Pending
- 2012-05-15 CN CN201280035150.5A patent/CN103796636B/zh not_active Expired - Fee Related
- 2012-05-15 BR BR112013029332-2A patent/BR112013029332A2/pt not_active Application Discontinuation
- 2012-05-15 KR KR1020207028301A patent/KR20200118228A/ko not_active Ceased
- 2012-05-15 JP JP2014510901A patent/JP6152092B2/ja not_active Expired - Fee Related
- 2012-05-15 EA EA201391701A patent/EA201391701A1/ru unknown
- 2012-05-15 KR KR1020137033180A patent/KR20140033408A/ko not_active Ceased
- 2012-05-15 KR KR1020237008221A patent/KR20230041081A/ko not_active Ceased
- 2012-05-15 KR KR1020197029484A patent/KR20190117803A/ko not_active Ceased
- 2012-05-15 CA CA3034552A patent/CA3034552C/en active Active
- 2012-05-15 EP EP12738595.3A patent/EP2709588B1/en active Active
- 2012-05-16 AR ARP120101721A patent/AR089553A1/es not_active Application Discontinuation
- 2012-05-16 AR ARP120101720A patent/AR086409A1/es not_active Application Discontinuation
-
2013
- 2013-11-11 IL IL229401A patent/IL229401A0/en unknown
- 2013-11-11 IL IL229400A patent/IL229400A0/en unknown
- 2013-12-09 ZA ZA2013/09264A patent/ZA201309264B/en unknown
- 2013-12-09 ZA ZA2013/09265A patent/ZA201309265B/en unknown
-
2017
- 2017-03-22 JP JP2017056679A patent/JP6594924B2/ja not_active Expired - Fee Related
- 2017-05-24 AU AU2017203470A patent/AU2017203470A1/en not_active Abandoned
- 2017-06-20 AU AU2017204182A patent/AU2017204182A1/en not_active Abandoned
-
2018
- 2018-08-27 JP JP2018158566A patent/JP2018199701A/ja active Pending
-
2019
- 2019-03-08 AU AU2019201618A patent/AU2019201618A1/en not_active Abandoned
- 2019-04-30 AU AU2019203067A patent/AU2019203067A1/en not_active Abandoned
- 2019-05-15 AU AU2019203400A patent/AU2019203400A1/en not_active Abandoned
- 2019-09-25 JP JP2019173990A patent/JP7017254B2/ja active Active
-
2020
- 2020-01-29 JP JP2020012807A patent/JP2020079257A/ja active Pending
- 2020-07-29 AU AU2020210227A patent/AU2020210227A1/en not_active Abandoned
- 2020-09-18 JP JP2020157216A patent/JP2021001206A/ja active Pending
- 2020-11-09 AU AU2020267162A patent/AU2020267162B2/en not_active Ceased
-
2022
- 2022-03-07 JP JP2022034334A patent/JP2022078222A/ja active Pending
- 2022-04-12 AU AU2022202402A patent/AU2022202402A1/en not_active Abandoned
- 2022-05-06 JP JP2022076671A patent/JP2022105175A/ja active Pending
-
2024
- 2024-08-23 AU AU2024216312A patent/AU2024216312A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024216312A1 (en) | Intranasal testosterone gel formulations and use thereof for treating male hypogonadism | |
| US20250064831A1 (en) | Controlled release topical testosterone formulations and methods | |
| US20250009756A1 (en) | Male Testosterone Titration Methods, Male Intranasal Testosterone Bio-Adhesive Gel Formulations and Use Thereof for Treating Hypogonadism and TRT | |
| US20240316063A1 (en) | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event | |
| HK1196287A (en) | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism | |
| HK1196287B (en) | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism | |
| HK1263036B (en) | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism | |
| HK1263036A1 (en) | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism | |
| EA039080B1 (ru) | Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: ACERUS PHARMACEUTICALS SRL Free format text: FORMER APPLICANT(S): TRIMEL BIOPHARMA SRL |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |